melatonin has been researched along with Osteosarcoma in 21 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has been proposed as a potent anticarcinogen presents a short half-life for osteosarcoma (OS)." | 8.02 | 3D-printing magnesium-polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures. ( Cheng, Z; Li, Q; Qu, J; Yuan, Z; Zhang, W; Zhang, Z; Zhao, D; Zhao, W; Zhu, X; Zhuang, X, 2021) |
| "Melatonin is recognized as an anti-angiogenic agent, but its function in the tumor microenvironment especially in osteosarcoma remains uncertain." | 7.96 | Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. ( Anuradha, D; Raghunandhakumar, S; Saravanan, S; Vimalraj, S, 2020) |
| "MTT, wound healing, transwell assay and western blotting were conducted to determine the effect of melatonin on osteosarcoma cell invasion and migration and downregulation of SOX9-mediated signaling." | 7.88 | Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. ( Fu, Q; He, J; Lai, L; Lian, W; Lin, N; Qu, H; Wang, C; Wang, Q; Xue, Y; Ye, Z; Zhong, L, 2018) |
| "In a previous study, we found that melatonin inhibits MG-63 osteosarcoma cell proliferation; however, the underlying mechanisms remain elusive." | 7.83 | Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells. ( Chen, D; Jiang, L; Li, Z; Liu, L; Liu, Y; Pan, Y; Pu, X; Reiter, RJ; Xu, Y, 2016) |
| "To evaluate the effects of melatonin (Mel) combined with cis-platinum (DDP) or methotrexate (MTX) on the proliferation of osteosarcoma cell line SaOS-2, and to explore whether Mel combined with DDP or MTX could play a synergistic antitumor effect." | 7.81 | Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2. ( Wang, YP; Yang, ZP, 2015) |
| "It seems established that the onset of osteosarcoma and the reduction in melatonin production run in parallel; this suggests that the decline in the cancer-inhibiting agent, melatonin, may contribute to the occurrence of osteosarcoma and that melatonin supplementation may have promise for preventing the development and progression of this condition." | 7.79 | Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. ( Liu, L; Reiter, RJ; Xu, Y, 2013) |
| "Melatonin was previously shown to inhibit proliferation of MCF-7 human breast cancer cells." | 7.70 | Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. ( Bianchi, P; Glencross, DK; Lottering, ML; Panzer, A; Seegers, JC; Stark, JH, 1998) |
| "Although bone cancer is relatively rare, it is a serious disease that often becomes metastatic, leading to an unsatisfactory prognosis." | 7.01 | Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review. ( Asemi, Z; Dana, PM; Reiter, RJ; Sadoughi, F; Yousefi, B, 2023) |
| "Melatonin treatment significantly downregulated the expression of lncRNA JPX in Saos-2, MG63 and U2OS cells." | 5.62 | Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells. ( Du, J; Li, B; Li, Y; Zou, J, 2021) |
| "Melatonin treatment resulted in strong antitumor activity, as evidenced not only by reductions in tumor cell vitality, adhesion ability, migration ability and glutathione (GSH) levels but also by increase in the apoptotic index and reactive oxygen species." | 5.39 | SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells. ( Cai, L; Cheng, Y; Feng, H; Gao, C; Jiang, P; Pan, H; Wang, C; Wang, J; Yang, Y, 2013) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Melatonin has been proposed as a potent anticarcinogen presents a short half-life for osteosarcoma (OS)." | 4.02 | 3D-printing magnesium-polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures. ( Cheng, Z; Li, Q; Qu, J; Yuan, Z; Zhang, W; Zhang, Z; Zhao, D; Zhao, W; Zhu, X; Zhuang, X, 2021) |
| "Melatonin is recognized as an anti-angiogenic agent, but its function in the tumor microenvironment especially in osteosarcoma remains uncertain." | 3.96 | Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. ( Anuradha, D; Raghunandhakumar, S; Saravanan, S; Vimalraj, S, 2020) |
| "MTT, wound healing, transwell assay and western blotting were conducted to determine the effect of melatonin on osteosarcoma cell invasion and migration and downregulation of SOX9-mediated signaling." | 3.88 | Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. ( Fu, Q; He, J; Lai, L; Lian, W; Lin, N; Qu, H; Wang, C; Wang, Q; Xue, Y; Ye, Z; Zhong, L, 2018) |
| "In a previous study, we found that melatonin inhibits MG-63 osteosarcoma cell proliferation; however, the underlying mechanisms remain elusive." | 3.83 | Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells. ( Chen, D; Jiang, L; Li, Z; Liu, L; Liu, Y; Pan, Y; Pu, X; Reiter, RJ; Xu, Y, 2016) |
| "To evaluate the effects of melatonin (Mel) combined with cis-platinum (DDP) or methotrexate (MTX) on the proliferation of osteosarcoma cell line SaOS-2, and to explore whether Mel combined with DDP or MTX could play a synergistic antitumor effect." | 3.81 | Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2. ( Wang, YP; Yang, ZP, 2015) |
| "It seems established that the onset of osteosarcoma and the reduction in melatonin production run in parallel; this suggests that the decline in the cancer-inhibiting agent, melatonin, may contribute to the occurrence of osteosarcoma and that melatonin supplementation may have promise for preventing the development and progression of this condition." | 3.79 | Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. ( Liu, L; Reiter, RJ; Xu, Y, 2013) |
| "Melatonin was previously shown to inhibit proliferation of MCF-7 human breast cancer cells." | 3.70 | Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. ( Bianchi, P; Glencross, DK; Lottering, ML; Panzer, A; Seegers, JC; Stark, JH, 1998) |
| "Although bone cancer is relatively rare, it is a serious disease that often becomes metastatic, leading to an unsatisfactory prognosis." | 3.01 | Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review. ( Asemi, Z; Dana, PM; Reiter, RJ; Sadoughi, F; Yousefi, B, 2023) |
| "Melatonin is known to inhibit cell proliferation in both tumor types." | 1.72 | Calcium acts as a central player in melatonin antitumor activity in sarcoma cells. ( Herrera, F; Martín, V; Puente-Moncada, N; Rodríguez, C; Sánchez-Sánchez, AM; Turos-Cabal, M, 2022) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic hydroxyurea dosage increased the biological therapy outcome by strengthening antitumor capability." | 1.72 | A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G; Di Bella, L; Moscato, I, 2022) |
| "Melatonin treatment significantly downregulated the expression of lncRNA JPX in Saos-2, MG63 and U2OS cells." | 1.62 | Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells. ( Du, J; Li, B; Li, Y; Zou, J, 2021) |
| "Melatonin treatment resulted in strong antitumor activity, as evidenced not only by reductions in tumor cell vitality, adhesion ability, migration ability and glutathione (GSH) levels but also by increase in the apoptotic index and reactive oxygen species." | 1.39 | SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells. ( Cai, L; Cheng, Y; Feng, H; Gao, C; Jiang, P; Pan, H; Wang, C; Wang, J; Yang, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 10 (47.62) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Zhao, W | 1 |
| Li, Q | 1 |
| Zhao, D | 1 |
| Qu, J | 1 |
| Yuan, Z | 1 |
| Cheng, Z | 1 |
| Zhu, X | 1 |
| Zhuang, X | 1 |
| Zhang, Z | 1 |
| Li, Y | 1 |
| Zou, J | 1 |
| Li, B | 1 |
| Du, J | 1 |
| Sánchez-Sánchez, AM | 1 |
| Turos-Cabal, M | 1 |
| Puente-Moncada, N | 1 |
| Herrera, F | 1 |
| Rodríguez, C | 1 |
| Martín, V | 1 |
| Hosseini, F | 1 |
| Shanehbandi, D | 1 |
| Soleimanpour, J | 1 |
| Yousefi, B | 3 |
| Alemi, F | 1 |
| Dana, PM | 1 |
| Sadoughi, F | 1 |
| Reiter, RJ | 5 |
| Asemi, Z | 1 |
| Di Bella, G | 1 |
| Di Bella, L | 1 |
| Borghetto, V | 1 |
| Moscato, I | 1 |
| Costanzo, E | 1 |
| Lu, KH | 2 |
| Lin, RC | 1 |
| Yang, JS | 1 |
| Yang, WE | 1 |
| Yang, SF | 2 |
| Chen, Y | 1 |
| Zhang, T | 1 |
| Liu, X | 1 |
| Li, Z | 2 |
| Zhou, D | 1 |
| Xu, W | 1 |
| Vimalraj, S | 1 |
| Saravanan, S | 1 |
| Raghunandhakumar, S | 1 |
| Anuradha, D | 1 |
| Niu, G | 1 |
| Qujeq, D | 1 |
| Marjani, A | 1 |
| Asadi, J | 1 |
| Wang, Z | 1 |
| Mir, SM | 1 |
| Qu, H | 1 |
| Xue, Y | 1 |
| Lian, W | 1 |
| Wang, C | 2 |
| He, J | 1 |
| Fu, Q | 1 |
| Zhong, L | 1 |
| Lin, N | 1 |
| Lai, L | 1 |
| Ye, Z | 1 |
| Wang, Q | 1 |
| Su, SC | 1 |
| Lin, CW | 1 |
| Hsieh, YH | 1 |
| Lin, YC | 1 |
| Chien, MH | 1 |
| Liu, L | 2 |
| Xu, Y | 2 |
| Cheng, Y | 1 |
| Cai, L | 1 |
| Jiang, P | 1 |
| Wang, J | 1 |
| Gao, C | 1 |
| Feng, H | 1 |
| Pan, H | 1 |
| Yang, Y | 1 |
| Wang, YP | 1 |
| Yang, ZP | 1 |
| Altındal, DÇ | 1 |
| Gümüşderelioğlu, M | 1 |
| Pan, Y | 1 |
| Chen, D | 1 |
| Liu, Y | 1 |
| Pu, X | 1 |
| Jiang, L | 1 |
| Panzer, A | 2 |
| Lottering, ML | 1 |
| Bianchi, P | 1 |
| Glencross, DK | 1 |
| Stark, JH | 1 |
| Seegers, JC | 1 |
| Starr, KW | 1 |
3 reviews available for melatonin and Osteosarcoma
| Article | Year |
|---|---|
Potential Mechanisms of Melatonin in Osteosarcoma and Bone-Related Neoplasms: Updated Review.
Topics: Antineoplastic Agents; Bone Neoplasms; Humans; Melatonin; Osteosarcoma; Sarcoma, Ewing | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug | 2019 |
1 trial available for melatonin and Osteosarcoma
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
18 other studies available for melatonin and Osteosarcoma
| Article | Year |
|---|---|
3D-printing magnesium-polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures.
Topics: Adult; Animals; Female; Humans; Magnesium; Male; Melatonin; Mice, Inbred BALB C; Mice, Nude; Osteosa | 2021 |
Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Exp | 2021 |
Calcium acts as a central player in melatonin antitumor activity in sarcoma cells.
Topics: Bone Neoplasms; Calcium; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal | 2022 |
Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplas | 2022 |
A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness.
Topics: Antioxidants; Bone Neoplasms; Butyric Acid; Humans; Hydroxyurea; Melatonin; Osteosarcoma; Tretinoin | 2022 |
Melatonin suppresses epithelial‑to‑mesenchymal transition in the MG‑63 cell line.
Topics: Cell Line, Tumor; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neop | 2020 |
Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Cell Line, Tumor; Chickens; Egg Yolk; Endothelial | 2020 |
Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells.
Topics: Apoptosis; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Graphite; Humans; Me | 2021 |
Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Disease Progression; Epith | 2018 |
Melatonin attenuates osteosarcoma cell invasion by suppression of C-C motif chemokine ligand 24 through inhibition of the c-Jun N-terminal kinase pathway.
Topics: Adolescent; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chemokine CCL24; Female; Humans; Melato | 2018 |
Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63.
Topics: Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Melaton | 2013 |
SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Glu | 2013 |
Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2.
Topics: Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Flow Cytomet | 2015 |
Melatonin releasing PLGA micro/nanoparticles and their effect on osteosarcoma cells.
Topics: Bone Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Humans; Lactic Acid; Melatonin; Nanop | 2016 |
Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin D1; Cyclin-Dependent | 2016 |
Melatonin in osteosarcoma: an effective drug?
Topics: Adolescent; Antineoplastic Agents; Bone Development; Bone Neoplasms; Child; Drug Therapy, Combinatio | 1997 |
Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Rel | 1998 |
Hormonal imbalance and the sarcomata.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Age Factors; Aged; Bone Neoplasms; Child, Preschool; | 1969 |